Postweaning multisystemic wasting syndrome and porcine circovirus from pigs

ABSTRACT

The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of pending U.S. applicationSer. No. 10/334,245, filed on Dec. 31, 2002, which is a continuation ofabandoned U.S. application Ser. No. 09/935,428, filed Aug. 20, 2001,which is a continuation of abandoned U.S. application Ser. No.09/209,961, filed Dec. 10, 1998, which claims priority to U.S.application Ser. No. 60/069,750, filed Dec. 16, 1997, and to U.S.application Ser. No. 60/069,233, filed Dec. 11, 1997. This applicationis also a continuation-in-part of pending U.S. application Ser. No.09/884,514, filed Jun. 19, 2001, which is a divisional of U.S.application Ser. No. 09/161,092, filed Sep. 25, 1998, now U.S. Pat. No.6,391,314, which is a continuation-in-part of U.S. application Ser. No.09/082,558, filed May 21, 1998, now U.S. Pat. No. 6,368,601, whichclaims priority to French Applications 97/12382, filed Oct. 3, 1997;98/00873, filed Jan. 22, 1998 and 98/03707, filed Mar. 20, 1998. Thisapplication is also a continuation-in-part of pending U.S. applicationSer. No. 09/680,228, filed Oct. 6, 2000, which is a continuation-in-partof U.S. application Ser. No. 09/583,350, filed May 31, 2000, now U.S.Pat. No. 6,517,843, which claims priority to U.S. application Ser. No.60/151,564, filed Aug. 31, 1999. This application is also acontinuation-in-part of pending U.S. application Ser. No. 09/784,962,filed Feb. 16, 2001 which is a divisional of U.S. application Ser. No.09/347,594, filed Jul. 1, 1999, now U.S. Pat. No. 6,217,883, whichclaims priority to French Application 98/08777, filed Jul. 6, 1998. Thisapplication is related to International application Serial No.PCT/CA98/01130, filed Dec. 11, 1998.

All of the foregoing applications, as well as all documents cited in theforegoing applications (“application documents”) and all documents citedor referenced in the application documents are incorporated herein byreference. Also, all documents cited in this application (“herein-citeddocuments”) and all documents cited or referenced in herein-citeddocuments are incorporated herein by reference. In addition, anymanufacturer's instructions or catalogues for any products cited ormentioned in each of the application documents or herein-cited documentsare incorporated by reference. Documents incorporated by reference intothis text or any teachings therein can be used in the practice of thisinvention. Documents incorporated by reference into this text are notadmitted to be prior art.

FIELD OF THE INVENTION

The present invention relates generally to viruses. More particularly,the present invention pertains to the isolation and characterization ofnew porcine circovirus (PCV) isolates from pigs displaying postweaningmultisystemic wasting syndrome (PMWS).

BACKGROUND OF THE INVENTION

Postweaning multisystemic wasting syndrome (PMWS) is a newly emergeddisease of pigs. PMWS appears to destroy the host immune system andcauses a high mortality rate in weaned pigs. This disease has a longincubation period, typically 3-8 weeks, and affects many organs ofinfected pigs. The PMWS syndrome detected in Canada, the United Statesand France is clinically characterized by a gradual loss of weight andby manifestations such as tachypnea, dyspnea and jaundice. From thepathological point of view, it is manifested by lymphocytic orgranulomateus infiltrations, lymphadenopathies and, more rarely, byhepatitis and lymphocytic or granulomateus nephritis (Clark, Proc. Am.Assoc. Swine Prac. 1997; 499-501; La Semaine Veterinaire No. 26,supplement to La Semaine Veterinaire 1996 (834); La Semaine Veterinaire1997 (857): 54; Gupi P. S. Nayar et al., Can. Vet. J, vol. 38, 1997;385-387). PMWS-affected piglets often die from respiratory failure andinterstitial pneumonia with histiocytic cell infiltration.

Porcine circovirus (PCV) causes worldwide infection in swine and ishighly contagious. PCV was originally detected as a noncytopathiccontaminant of porcine kidney (PK15) cell lines. PCV has been classifiedinto the new virus family Circoviridae. These viruses are small,nonenveloped agents with a single-stranded circular DNA genome.

A variety of circoviruses have been identified in a range of animalspecies including PCV, chicken anemia virus (CAV), beak and featherdisease virus (BFDV) of psittacine birds, plant viruses includingsubterranean clover stunt virus (SCSV), coconut foliar decay virus(CFDV) and banana bunch top virus (BBTV). There do not appear to be DNAsequence homologies or common antigenic determinants among the currentlyrecognized circoviruses. Todd et al. (1991) Arch. Virol. 17:129-135.

Members in the circovirus family have been shown to cause anemia,immunodeficiency-related diseases and to infect macrophage cells invitro. PCV has only recently been implicated in PMWS. See, e.g., Elliset al. (1998) Can. Vet. J. 39:44-51 and Gopi et al. (1997) Can. Vet. J.38:385-386. However, the etiologic association of PCV with PMWS has beenquestioned due to the ubiquitous presence of PCV in the pig population.Additionally, experimental infections of pigs with PCV inocula, derivedfrom contaminated PK15 cell cultures, have failed to produce clinicaldisease. See, e.g., Tischer et al. (1986) Arch. Virol. 91:271-276.

Infectious agents of swine, especially viruses, not only profoundlyaffect the farming industry, but pose potential public health risks tohumans, due to the increased interest in the use of pig organs forxenotransplantation in humans. Previous diagnosis of PMWS disease hasbeen based on histopathological examination. Accordingly, there is aneed for improved methods of diagnosing the presence of PMWS-associatedpathogens, as well as for preventing PMWS disease.

SUMMARY OF THE INVENTION

The present invention is based on the discovery of a new virus,designated “PCV Type II” or “PCVII” herein, isolated from homogenizedtissues of PMWS-affected piglets. Characterization of the virus showsthat it shares common features with the nonpathogenic porcine circovirusobtained from persistently infected PK15 cells, designated “PCV Type I”or “PCVI” herein. The entire DNA genome of a novel PCV variant, PCVII412, as well as several additional PCVII isolates, have been cloned andsequenced. Portions of these DNA sequences are useful as probes todiagnose the presence of virus in clinical samples, and to isolate othernaturally occurring variants of the virus. An understanding of thegenomic sequence of PCVII also makes available the polypeptide sequencesof the various proteins encoded within the open reading frames of theviral genome and permits production of these peptides or portionsthereof which are useful as standards or reagents in diagnostic testsand as components of vaccines. Protective antibodies may also be raisedfrom the proteins and may be produced in polyclonal or monoclonal form.

The availability of the entire PCVII sequence thus permits the designand construction of polypeptides which may either serve as vaccines ordiagnostic reagents, or as intermediates in the production of monoclonalantibody (Mab) preparations useful in passive immunotherapy againstPMWS, or as intermediates in the production of antibodies useful asdiagnostic reagents.

Accordingly, in one aspect, the invention relates to polynucleotidesuseful for the production of PCVII diagnostics and vaccines derived fromthe PCVII genome. In one particular embodiment, the polynucleotides arecapable of selectively hybridizing to a PCVII nucleotide sequence andcomprise at least about 8 contiguous nucleotides derived from, orcomplementary to, a PCVII sequence depicted in FIGS. 4A-4C (SEQ ID NO:1,SEQ ID NO:11 and SEQ ID NO:12). In another embodiment, thepolynucleotide encodes an immunogenic PCVII polypeptide having at leastabout 85% identity to a polypeptide selected from the group consistingof a polypeptide derived from (a) open reading frame (ORF) 1 (SEQ IDNO:3), (b) ORF 2 (SEQ ID NO:9), (c) ORF 3 (SEQ ID NO:7), (d) ORF 4 (SEQID NO:20), (e) ORF 5 (SEQ ID NO:21), (f) ORF 6 (SEQ ID NO:5), and (g)immunogenic fragments of (a)-(f) comprising at least about 5 aminoacids. In a particularly preferred embodiment, the polynucleotideencodes the polypeptide of ORF 6 (SEQ ID NO:5), or immunogenic fragmentsthereof.

The invention thus relates to utilizing these polynucleotide sequencesor portions thereof as oligomeric probes, for production of peptideswhich can serve as diagnostic reagents or as vaccine antigens, to thepeptides themselves, and to polyclonal and monoclonal antibodies usefulin diagnosis and treatment of the disease.

Other aspects of the invention include expression systems which arecapable of effecting the production of a desired protein encoded bysequences derived from the complete genome, to recombinant vectorscontaining such systems or portions thereof, to recombinant host cellstransformed with such vectors, to proteins produced by the transformedcells, and to vaccines prepared from such proteins. In addition, theinvention relates to peptide sequences representing epitopes encoded bythe genome, and to such sequences covalently linked to label or tocarrier proteins. Also encompassed by the present invention are thevarious ORFs of the PCVII genome, as well as the proteins encoded bythese ORFs, and portions thereof.

The invention also relates to the methods of preparing polypeptidecompositions, such as vaccines and immunodiagnostic compositions, andimmunoglobulins, and to immunoassays and kits for assays containing theprimers, probes, polypeptides, and/or immunoglobulins. In oneembodiment, then, the invention pertains to a method of detecting PCVIIantibodies in a biological sample comprising:

(a) providing a biological sample;

(b) reacting the biological sample with an immunogenic PCVII polypeptideas described above, under conditions which allow PCVII antibodies, whenpresent in the biological sample, to bind to the PCVII polypeptide toform an antibody/antigen complex; and

(c) detecting the presence or absence of the complex, thereby detectingthe presence or absence of PCVII antibodies in the sample.

In another embodiment, the invention is directed to a nucleic acidhybridization assay for detecting PCVII homologous sequences in abiological sample comprising:

(a) incubating the biological sample with a polynucleotide according toclaim 1 under conditions which promote the formation of nucleic acidcomplexes between the polynucleotide and PCVII nucleic acid present inthe biological sample; and

(b) detecting the complexes containing the polynucleotide.

These and other aspects and features of the invention will be more fullyappreciated when the following detailed description of the invention isread in conjunction with the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

The following Detailed Description, given by way of example, but notintended to limit the invention to specific embodiments described, maybe understood in conjunction with the accompanying drawings,incorporated herein by reference, in which:

FIG. 1 shows a diagram of PCVII 412, showing the location of the openreading frames.

FIGS. 2A-2C show the nucleotide sequence for the PCVII 412 genome (SEQID NO:1). Both senses are shown. The amino acid sequences correspondingto the translation products of the various ORFs are also shown asindicated: ORF 1 (SEQ ID NO:3); ORF 2 (SEQ ID NO:9); ORF 3 (SEQ IDNO:7); ORF 4 (SEQ ID NO:20); ORF 5 (SEQ ID NO:21); and ORF 6 (SEQ IDNO:5).

FIGS. 3A-3D show comparisons of amino acid sequences from open readingframes of PCVII 412 versus corresponding open reading frames of PCVIisolated from PK15 cells. FIG. 3A shows the amino acid sequence of ORF 1of PCVII 412 (top line, SEQ ID NO:3) compared to the corresponding ORFfrom PCVI (bottom line, SEQ ID NO:4). FIG. 3B shows the amino acidsequence of ORF 6 of PCVII 412 (top line, SEQ ID NO:S) compared to thecorresponding ORF from PCVI (bottom line, SEQ ID NO:6). FIG. 3C showsthe amino acid sequence of ORF 3 of PCVII 412 (top line, SEQ ID NO:7)compared to the corresponding ORF from PCVI (bottom line, SEQ ID NO:8).FIG. 3D shows the amino acid sequence of ORF 2 of PCVII 412 (top line,SEQ ID NO:9) compared to the corresponding ORF from PCVI (bottom line,SEQ ID NO:10).

FIGS. 4A-4B show comparisons of the nucleotide sequences of various PCVisolates: PCVI from PK15 cells. (SEQ ID NO:2), PCVII 412 (SEQ ID NO:1),PCVII 9741 (SEQ ID NO:11) and PCVII B9 (SEQ ID NO:12).

FIG. 5 shows the results of multiplex PCR used for the detection of PCVinfection. The assay both identified PCV infection and distinguishedbetween the presence of PCVI and PCVII. Lane 1 is a molecular weightmarker. Lanes 2-4 are controls in the order of PCVII, PCVI and negative.Lanes 5-13 are blood samples collected from piglets from a PMWS-affectedherd.

FIG. 6 shows the results of multiplex PCR conducted on various tissuesamples from a PMWS-affected piglet. Lane 1 in both rows is a molecularweight marker. Lane 2 in the top row is a positive PCVII control whilelane 3 is a negative control. The remaining lanes are various tissuesamples collected from the PMWS-affected piglet.

DETAILED DESCRIPTION OF THE INVENTION

The practice of the present invention will employ, unless otherwiseindicated, conventional techniques of molecular biology, microbiology,recombinant DNA technology, and immunology, which are within the skillof the art. Such techniques are explained fully in the literature. See,e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A LaboratoryManual, Vols. I, II and III, Second Edition (1989); DNA Cloning, Vols. Iand II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gaited. 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds.1984); Animal Cell Culture (R. K. Freshney ed. 1986); Immobilized Cellsand Enzymes (IRL press, 1986); Perbal, B., A Practical Guide toMolecular Cloning (1984); the series, Methods In Enzymology (S. Colowickand N. Kaplan eds., Academic Press, Inc.); and Handbook of ExperimentalImmunology, Vols. I-IV (D. M. Weir and C. C. Blackwell eds., 1986,Blackwell Scientific Publications).

Before describing the present invention in detail, it is to beunderstood that this invention is not limited to particular DNA,polypeptide sequences or process parameters as such may, of course,vary. It is also to be understood that the terminology used herein isfor the purpose of describing particular embodiments of the inventiononly, and is not intended to be limiting.

It must be noted that, as used in this specification and the appendedclaims, the singular forms “a”, “an” and “the” include plural referentsunless the content clearly dictates otherwise. Thus, for example,reference to “an antigen” includes a mixture of two or more antigens,reference to “an excipient” includes mixtures of two or more excipients,and the like.

The following amino acid abbreviations are used throughout the text:

Alanine: Ala (A) Arginine: Arg (R)

Asparagine: Asn (N) Aspartic acid: Asp (D)

Cysteine: Cys (C) Glutamine: Gln (Q)

Glutamic acid: Glu (E) Glycine: Gly (G)

Histidine: His (H) Isoleucine: Ile (I)

Leucine: Leu (L) Lysine: Lys (K)

Methionine: Met (M) Phenylalanine: Phe (F)

Proline: Pro (P) Serine: Ser (S)

Threonine: Thr (T) Tryptophan: Trp (W)

Tyrosine: Tyr (Y) Valine: Val (V)

A. Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which the invention pertains. Although a number of methodsand materials similar or equivalent to those described herein can beused in the practice of the present invention, the preferred materialsand methods are described herein.

In describing the present invention, the following terms will beemployed, and are intended to be defined as indicated below.

The terms “PCVII protein,” “PMWS protein” or a nucleotide sequenceencoding the same, intend a protein or a nucleotide sequence,respectively, which is derived from a novel PCVII isolate, as describedherein. The nucleotide sequences of several PCVII isolates are shown inFIGS. 4A-4B and the amino acid sequences corresponding to the sixidentified PCVII ORFs are shown in FIGS. 2A-2C. However, a PCVII or PMWSprotein, or a gene encoding the same, as defined herein is not limitedto the depicted sequence.

Further, as used herein, a nucleotide sequence “derived from” a PCVIIgenome or its complement refers to a sequence which retains theessential properties of the illustrated polynucleotide, representing aportion of the entire sequence from which it is derived, for the purposeintended. A specific, but nonlimiting, example of such derivation isrepresented by a sequence which encodes an identical, or substantiallyidentical amino acid sequence, but, because of codon degeneracy,utilizes different specific codons; another example is a sequencecomplementary to the viral DNA. A probe or oligonucleotide useful indiagnostic tests needs to retain the complementarity of the sequenceshown but may be shorter than the entire sequence or may skip overportions of it. However, for use in manipulation or expression,nucleotide changes are often desirable to create or delete restrictionsites, provide processing sites, or to alter the encoded amino acidsequence in ways which do not adversely affect functionality. The terms“nucleotide sequence” and “polynucleotide” refer both to ribonucleotideand a deoxyribonucleotide sequences and include both the genomic strandand its complementary sequence.

A sequence “derived from” the nucleotide sequence which comprises thegenome of a PCVII isolate therefore refers to a sequence which iscomprised of a sequence corresponding to a region of the genomicnucleotide sequence (or its complement), or a combination of regions ofthat sequence modified in ways known in the art to be consistent withits intended use. These sequences are, of course, not necessarilyphysically derived from the nucleotide sequence of the gene, but referto polynucleotides generated in whatever manner which are based on theinformation provided by the sequence of bases in the region(s) fromwhich the polynucleotide is derived. For example, regions from whichtypical DNA sequences can be “derived” include regions encoding specificepitopes. Similarly, a peptide “derived from” a PCVII ORF refers to anamino acid sequence substantially identical to that of thesepolypeptides or a portion thereof, having the same biological propertiesas that portion.

Furthermore, the derived protein or nucleotide sequences need not bephysically derived from the genes described above, but may be generatedin any manner, including for example, chemical synthesis, isolation(e.g., from a PCVII isolate) or by recombinant production, based on theinformation provided herein. Additionally, the term intends proteinshaving amino acid sequences substantially homologous (as defined below)to contiguous amino acid sequences encoded by the genes, which displayimmunological activity.

Thus, the terms intend full-length, as well as immunogenic, truncatedand partial sequences, and active analogs and precursor forms of theproteins. Also included in the term are nucleotide fragments of theparticular gene that include at least about 8 contiguous base pairs,more preferably at least about 10-20 contiguous base pairs, and even atleast about 25 to 50 or 75 or more contiguous base pairs of the gene.Such fragments are useful as probes, in diagnostic methods, and for therecombinant production of proteins, as discussed more fully below.

The terms also include proteins in neutral form or in the form of basicor acid addition salts depending on the mode of preparation. Such acidaddition salts may involve free amino groups and basic salts may beformed with free carboxyls. Pharmaceutically acceptable basic and acidaddition salts are discussed further below. In addition, the proteinsmay be modified by combination with other biological materials such aslipids and saccharides, or by side chain modification, such asacetylation of amino groups, phosphorylation of hydroxyl side chains,oxidation of sulfhydryl groups, glycosylation of amino acid residues, aswell as other modifications of the encoded primary sequence.

The term therefore intends deletions, additions and substitutions to thesequence, so long as the polypeptide functions to produce animmunological response as defined herein. In this regard, particularlypreferred substitutions will generally be conservative in nature, i.e.,those substitutions that take place within a family of amino acids. Forexample, amino acids are generally divided into four families: (1)acidic—aspartate and glutamate; (2) basic—lysine, arginine, histidine;(3) non-polar—alanine, valine, leucine, isoleucine, proline,phenylalanine, methionine, tryptophan; and (4) uncharged polar—glycine,asparagine, glutamine, cystine, serine threonine, tyrosine.Phenylalanine, tryptophan, and tyrosine are sometimes classified asaromatic amino acids. For example, it is reasonably predictable that anisolated replacement of leucine with isoleucine or valine, or viceversa; an aspartate with a glutamate or vice versa; a threonine with aserine or vice versa; or a similar conservative replacement of an aminoacid with a structurally related amino acid, will not have a majoreffect on the biological activity. Proteins having substantially thesame amino acid sequence as the reference molecule, but possessing minoramino acid substitutions that do not substantially affect theimmunogenicity of the protein, are therefore within the definition ofthe reference polypeptide.

An “open reading frame” or “ORF” is a region of a polynucleotidesequence which encodes a polypeptide.

By “postweaning multisystemic wasting syndrome” or “PMWS” is meant adisease of vertebrate animals, in particular pigs, which ischaracterized clinically by progressive weight loss, tachypnea, dyspneaand jaundice. Consistent pathologic changes include lymphocytic togranulomatous interstitial pneumonia, lymphadenopathy, and, lessfrequently, lymphocytic to granulomatous hepatitis and nephritis. See,e.g., Clark, E. G. Proc. Am. Assoc. Swine Pract. 1997:499-501; andHarding, J. Proc. Am. Assoc. Swine Pract. 1997:503.

An “isolated” nucleic acid molecule is a nucleic acid molecule separateand discrete from the whole organism with which the molecule is found innature; or a nucleic acid molecule devoid, in whole or part, ofsequences normally associated with it in nature; or a sequence, as itexists in nature, but having heterologous sequences (as defined below)in association therewith.

The term “vaccine composition” intends any pharmaceutical compositioncontaining an antigen, which composition can be used to prevent or treata disease or condition in a subject. The term thus encompasses bothsubunit vaccines, as described below, as well as compositions containingwhole killed, attenuated or inactivated microbes.

By “subunit vaccine composition” is meant a composition containing atleast one immunogenic polypeptide, but not all antigens, derived from orhomologous to an antigen from a pathogen of interest. Such a compositionis substantially free of intact pathogen cells or particles, or thelysate of such cells or particles. Thus, a “subunit vaccine composition”is prepared from at least partially purified (preferably substantiallypurified) immunogenic polypeptides from the pathogen, or recombinantanalogs thereof. A subunit vaccine composition can comprise the subunitantigen or antigens of interest substantially free of other antigens orpolypeptides from the pathogen.

The compositions of the invention can include any pharmaceuticallyacceptable carrier known in the art.

The term “epitope” refers to the site on an antigen or hapten to whichspecific B cells and/or T cells respond. The term is also usedinterchangeably with “antigenic determinant” or “antigenic determinantsite”. Antibodies that recognize the same epitope can be identified in asimple immunoassay showing the ability of one antibody to block thebinding of another antibody to a target antigen.

An “immunological response” to a composition or vaccine is thedevelopment in the host of a cellular and/or antibody-mediated immuneresponse to the composition or vaccine of interest. Usually, an“immunological response” includes but is not limited to one or more ofthe following effects: the production of antibodies, B cells, helper Tcells, suppressor-T cells, and/or cytotoxic T cells and/or γδ T cells,directed specifically to an antigen or antigens included in thecomposition or vaccine of interest. Preferably, the host will displayeither a therapeutic or protective immunological response such thatresistance to new infection will be enhanced and/or the clinicalseverity of the disease reduced. Such protection will be demonstrated byeither a reduction or lack of symptoms normally displayed by an infectedhost, a quicker recovery time and/or a lowered viral titer in theinfected host.

The terms “imununogenic” protein or polypeptide refer to an amino acidsequence which elicits an immunological response as described above. An“immunogenic” protein or polypeptide, as used herein, includes thefull-length sequence of the protein, analogs thereof, or immunogenicfragments thereof. By “immunogenic fragment” is meant a fragment of aprotein which includes one or more epitopes and thus elicits theimmunological response described above. Such fragments can be identifiedusing any number of epitope mapping techniques, well known in the art.See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology,Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, N.J. Forexample, linear epitopes may be determined by e.g., concurrentlysynthesizing large numbers of peptides on solid supports, the peptidescorresponding to portions of the protein molecule, and reacting thepeptides with antibodies while the peptides are still attached to thesupports. Such techniques are known in the art and described in, e.g.,U.S. Pat. No. 4,708,871; Geysen et al. (1984) Proc. Natl. Acad. Sci. USA81:3998-4002; Geysen et al. (1986) Molec. Immunol. 23:709-715, allincorporated herein by reference in their entireties. Similarly,conformational epitopes are readily identified by determining spatialconformation of amino acids such as by, e.g., x-ray crystallography and2-dimensional nuclear magnetic resonance. See, e.g., Epitope MappingProtocols, supra.

Synthetic antigens are also included within the definition, for example,polyepitopes, flanking epitopes, and other recombinant or syntheticallyderived antigens. See, e.g., Bergmann et al. (1993) Eur. J. Immunol.23:2777-2781; Bergmann et al. (1996) J. Immunol. 157:3242-3249;Suhrbier, A. (1997) Immunol. and Cell Biol. 75:402-408; Gardner et al.(1998) 12th World AIDS Conference, Geneva, Switzerland, Jun. 28-Jul. 3,1998.

Immunogenic fragments, for purposes of the present invention, willusually include at least about 3 amino acids, preferably at least about5 amino acids, more preferably at least about 10-15 amino acids, andmost preferably 25 or more amino acids, of the molecule. There is nocritical upper limit to the length of the fragment, which could comprisenearly the full-length of the protein sequence, or even a fusion proteincomprising two or more epitopes of the protein.

Any of the above immunogenic proteins, immunogenic polypeptides,synthetic antigens, or immunogenic fragments can be used to raiseantibodies in a host.

“Native” proteins or polypeptides refer to proteins or polypeptidesisolated from the source in which the proteins naturally occur.“Recombinant” polypeptides refer to polypeptides produced by recombinantDNA techniques; i.e., produced from cells transformed by an exogenousDNA construct encoding the desired polypeptide. “Synthetic” polypeptidesare those prepared by chemical synthesis.

A “vector” is a replicon, such as a plasmid, phage, or cosmid, to whichanother DNA segment may be attached so as to bring about the replicationof the attached segment.

A DNA “coding sequence” or a “nucleotide sequence encoding” a particularprotein, is a DNA sequence which is transcribed and translated into apolypeptide in vitro or in vivo when placed under the control ofappropriate regulatory elements. The boundaries of the coding sequenceare determined by a start codon at the 5′ (amino) terminus and atranslation stop codon at the 3′ (carboxy) terminus. A coding sequencecan include, but is not limited to, procaryotic sequences, cDNA fromeucaryotic mRNA, genomic DNA sequences from eucaryotic (e.g., mammalian)DNA, and even synthetic DNA sequences. A transcription terminationsequence will usually be located 3′ to the coding sequence.

DNA “control elements” refers collectively to promoters, ribosomebinding sites, polyadenylation signals, transcription terminationsequences, upstream regulatory domains, enhancers, and the like, whichcollectively provide for the transcription and translation of a codingsequence in a host cell. Not all of these control sequences need alwaysbe present in a recombinant vector so long as the desired gene iscapable of being transcribed and translated.

“Operably linked” refers to an arrangement of elements wherein thecomponents so described are configured so as to perform their usualfunction. Thus, control elements operably linked to a coding sequenceare capable of effecting the expression of the coding sequence. Thecontrol elements need not be contiguous with the coding sequence, solong as they function to direct the expression thereof. Thus, forexample, intervening untranslated yet transcribed sequences can bepresent between a promoter and the coding sequence and the promoter canstill be considered “operably linked” to the coding sequence.

A control element, such as a promoter, “directs the transcription” of acoding sequence in a cell when RNA polymerase will bind the promoter andtranscribe the coding sequence into mRNA, which is then translated intothe polypeptide encoded by the coding sequence.

A “host cell” is a cell which has been transformed, or is capable oftransformation, by an exogenous nucleic acid molecule.

A cell has been “transformed” by exogenous DNA when such exogenous DNAhas been introduced inside the cell membrane. Exogenous DNA may or maynot be integrated (covalently linked) into chromosomal DNA making up thegenome of the cell. In procaryotes and yeasts, for example, theexogenous DNA may be maintained on an episomal element, such as aplasmid. With respect to eucaryotic cells, a stably transformed cell isone in which the exogenous DNA has become integrated into the chromosomeso that it is inherited by daughter cells through chromosomereplication. This stability is demonstrated by the ability of theeucaryotic cell to establish cell lines or clones comprised of apopulation of daughter cells containing the exogenous DNA.

“Homology” refers to the percent identity between two polynucleotide ortwo polypeptide moieties. Two DNA, or two polypeptide sequences are“substantially homologous” to each other when the sequences exhibit atleast about 80%-85%, preferably at least about 90%, and most preferablyat least about 95%-98% sequence identity over a defined length of themolecules. As used herein, substantially homologous also refers tosequences showing complete identity to the specified DNA or polypeptidesequence.

Percent identity can be determined by a direct comparison of thesequence information between two molecules by aligning the sequences,counting the exact number of matches between the two aligned sequences,dividing by the length of the shorter sequence, and multiplying theresult by 100. Readily available computer programs can be used to aid inthe analysis, such as ALIGN, Dayhoff, M. O. in Atlas of Protein Sequenceand Structure M. O. Dayhoff ed., 5 Suppl. 3:353-358, National biomedicalResearch Foundation, Washington, D.C., which adapts the local homologyalgorithm of Smith and Waterman (1981) Advances in Appl. Math. 2:482-489for peptide analysis. Programs for determining nucleotide sequenceidentity are available in the Wisconsin Sequence Analysis Package,Version 8 (available from Genetics Computer Group, Madison, Wis.) forexample, the BESTFIT, FASTA and GAP programs, which also rely on theSmith and Waterman algorithm. These programs are readily utilized withthe default parameters recommended by the manufacturer and described inthe Wisconsin Sequence Analysis Package referred to above.

Alternatively, homology can be determined by hybridization ofpolynucleotides under conditions which form stable duplexes betweenhomologous regions, followed by digestion with single-stranded-specificnuclease(s), and size determination of the digested fragments. DNAsequences that are substantially homologous can be identified in aSouthern hybridization experiment under, for example, stringentconditions, as defined for that particular system. Defining appropriatehybridization conditions is within the skill of the art. See, e.g.,Sambrook et al., supra; DNA Cloning, supra; Nucleic Acid Hybridization,supra.

Two nucleic acid fragments are considered to be “selectivelyhybridizable” to a PCVII polynucleotide, if they are capable ofspecifically hybridizing to a PCVII nucleic acid or a variant thereof(e.g., a probe that hybridizes to a PCVII nucleic acid but not topolynucleotides from other members of the circovirus family) orspecifically priming a polymerase chain reaction: (i) under typicalhybridization and wash conditions, as described, for example, inSambrook et al., supra and Nucleic Acid Hybridization, supra, (ii) usingreduced stringency wash conditions that allow at most about 25-30%basepair mismatches, for example: 2×SSC, 0.1% SDS, room temperaturetwice, 30 minutes each; then 2×SSC, 0.1% SDS, 37° C. once, 30 minutes;then 2×SSC room temperature twice, 10 minutes each, or (iii) selectingprimers for use in typical polymerase chain reactions (PCR) understandard conditions (described for example, in Saiki, et al. (1988)Science 239:487-491), which result in specific amplification ofsequences of PCVII or its variants.

The term “functionally equivalent” intends that the amino acid sequenceof a protein is one that will elicit a substantially equivalent orenhanced immunological response, as defined above, as compared to theresponse elicited by a reference amino acid sequence, or an immunogenicportion thereof.

A “heterologous” region of a DNA construct is an identifiable segment ofDNA within or attached to another DNA molecule that is not found inassociation with the other molecule in nature. Thus, when theheterologous region encodes a viral gene, the gene will usually beflanked by DNA that does not flank the viral gene in the genome of thesource virus. Another example of the heterologous coding sequence is aconstruct where the coding sequence itself is not found in nature (e.g.,synthetic sequences having codons different from the native gene).Allelic variation or naturally occurring mutational events do not giverise to a heterologous region of DNA, as used herein.

The term “treatment” as used herein refers to either (i) the preventionof infection or reinfection (prophylaxis), or (ii) the reduction orelimination of symptoms of the disease of interest (therapy).

As used herein, a “biological sample” refers to a sample of tissue orfluid isolated from a subject, including but not limited to, forexample, blood, plasma, serum, fecal matter, urine, bone marrow, bile,spinal fluid, lymph tissue and lymph fluid, samples of the skin,external secretions of the skin, respiratory, intestinal, andgenitourinary tracts, tears, saliva, milk, blood cells, organs, biopsiesand also samples of in vitro cell culture constituents including but notlimited to conditioned media resulting from the growth of cells andtissues in culture medium, e.g., recombinant cells, and cell components.

As used herein, the terms “label” and “detectable label” refer to amolecule capable of detection, including, but not limited to,radioactive isotopes, fluorescers, chemiluminescers, enzymes, enzymesubstrates, enzyme cofactors, enzyme inhibitors, chromophores, dyes,metal ions, metal sols, ligands (e.g., biotin or haptens) and the like.The term “fluorescer” refers to a substance or a portion thereof whichis capable of exhibiting fluorescence in the detectable range.Particular examples of labels which may be used under the inventioninclude fluorescein, rhodamine, dansyl, umbelliferone, Texas red,luminol, NADPH and α-β.-galactosidase.

By “vertebrate subject” is meant any member of the subphylum cordata,including, without limitation, mammals such as cattle, sheep, pigs,goats, horses, and man; domestic animals such as dogs and cats; andbirds, including domestic, wild and game birds such as cocks and hensincluding chickens, turkeys and other gallinaceous birds. The term doesnot denote a particular age. Thus, adult and newborn animals, as well asfetuses, are intended to be covered.

B. General Methods

Central to the present invention is the discovery of a new circovirustermed “PCVII” herein, isolated from PMWS-affected pigs. The usefulmaterials and processes of the present invention are made possible bythe discovery of a family of nucleotide sequences, each containing anentire genome of a novel PCVII virus. The availability of this family ofpolynucleotides, first, permits the isolation of other members of thegenome family which differ by small heterogeneities. Second, it permitsthe construction of DNA fragments and proteins useful in diagnosis. Forexample, oligomers of at least about 8-10 nucleotides or more,preferably, oligomers comprising at least about 15-20 nucleotides, areuseful as hybridization probes in disease diagnosis. Such probes may beused to detect the presence of the viral genome in, for example, sera ofsubjects suspected of harboring the virus. Similarly, the genes encodingthe proteins can be cloned and used to design probes to detect andisolate homologous genes in other viral isolates.

The PCVII sequences also allow the design and production ofPCVII-specific polypeptides which are useful as diagnostic reagents forthe presence of antibodies raised against PCVII in serum or blood.Antibodies against these polypeptides are also useful as diagnostics.Because several open reading frames can be deciphered in the context ofthe complete genome, the primary structures of PCVII-related proteinscan be deduced. Finally, knowledge of the gene sequences also enablesthe design and production of vaccines effective against PCVII and henceuseful for the prevention of PMWS and also for the production ofprotective antibodies.

Sequencing information available from the genome allows the amino acidsequence of the various polypeptides encoded by the viral genome to bededuced and suitable epitopes identified. The full-length proteinsencoded by the several ORFs identified in the PCVII genome, or suitableportions thereof, can be produced using fragments of the relevant DNAwhich are obtained and expressed independently, thus providing desiredpolypeptides using recombinant techniques. Both procaryotic andeucaryotic hosts are useful for such expression. Short polypeptidefragments may also be chemically synthesized and linked to carrierproteins for use as vaccines. In addition, epitopes may be producedlinked to a protein conferring immunogenicity. The proteins thusproduced may themselves be used as vaccines, or may be used to induceimmunocompetent B cells in hosts, which B cells can then be used toproduce hybridomas that secrete antibodies useful in passiveimmunotherapy.

More particularly, the complete genetic sequences for three isolates ofPCVII, PCVII 412 (SEQ ID NO:1), PCVII 9741 (SEQ ID NO:11), AND PCVII B9(SEQ ID NO:12), are shown in FIGS. 4A-4B. The percent nucleotidesequence homologies among the various isolates of PCVII are more than99% identical. The newly discovered viral genome shares approximately76% identity with PCV isolated from infected PK15 cells at thenucleotide level (termed “PCVI” herein). As described further in theexamples, nucleotide insertions and deletions (indels) have been foundin three regions.

As shown in FIG. 1, the new virus contains at least six potential openreading frames (ORFs) encoding proteins comprising more than 50 aminoacid residues, while PCVI derived from PK15 has seven potential ORFs.The ORFs for representative PCVII isolates occur at the followingnucleotide positions, using the numbering of the PCVII isolates shown inFIGS. 4A-4B: ORF 1  51 to 992 ORF 2 671 to 360 ORF 3 565 to 389 ORF 4553 to 729 ORF 5 1016 to 1174 ORF 6 1735 to 1037

The polypeptides encoded by the six ORFs are shown in FIGS. 2A-2C.

The main cellular targets for PCVII are mononuclear cells in theperipheral blood, likely macrophage cells, although the virus is alsofound in various tissues and organs in infected animals. The affectedmacrophages lose their normal function, causing damage to the hostimmune system, leading to death.

The cloning and sequencing of the novel circoviruses has providedinformation about the causative agent of PMWS. As explained above, thesequencing information, as well as the clones and its gene products, areuseful for diagnosis and in vaccine development. In particular, PCR andantibody-based diagnostic methods are useful in the diagnosis of thedisease and were used herein to specifically identify and differentiatethis novel PCVII virus from PCVI derived from persistently infected PK15cells. The sequencing information is also useful in the design ofspecific primers, to express viral-specific gene products, to study theviral structure, to generate specific antibodies and to identifyvirulent genes in porcine circovirus-related diseases.

B.1. Preparation of the PCVII Gene Sequence

The new viral genomes of PCVII were obtained from viruses isolated fromtissue of PMWS-affected pigs. Viral DNA was extracted from variablesources, including pellets of infected Dulac and Vero cells, peripheralblood buffy-coat cells, tissues from infected animals and serum. DNA wasextracted from the samples using techniques discussed more fully in theexamples.

By comparing the sequence and structural similarity among the knownviruses in the circovirus family, a unique primer was designed takingadvantage of the complementary sequences of a conserved stem loopstructure. One-primer PCR was then performed and the products cloned.Two full-length viral genomes in different orientations inserted into aplasmid vector were completely sequenced in both directions. AdditionalPCR products were made and sequenced to ensure the fidelity of theprimer/stem loop region.

Using similar primers, other PCVII isolates, including PCVII 9741, andPCVII B9, were obtained. This appears to be the first time a circovirushas been cloned from viral particles instead of from a replicated formof DNA.

The description of the method to retrieve the PCVII genome is, ofcourse, mostly of historical interest. The resultant sequence isprovided herein, and the entire sequence, or any portion thereof, couldalso be prepared using synthetic methods, or by a combination ofsynthetic methods with retrieval of partial sequences using methodssimilar to those here described.

B.2. Production of PCVII Proteins

The availability of PCVII genomic sequences permits construction ofexpression vectors encoding viral polypeptides and antigenically activeregions thereof, derived from the PCVII genome. Fragments encoding thedesired proteins can be obtained from cDNA clones using conventionalrestriction digestion or by synthetic methods and are ligated intovectors, for example, containing portions of fusion sequences such asβ-galactosidase. Any desired portion of the PCVII genome containing anopen reading frame can be obtained as a recombinant protein, such as amature or fusion protein, or can be provided bychemical synthesis orgeneral recombinant means.

It is readily apparent that PCVII proteins encoded by theabove-described DNA sequences, active fragments, analogs and chimericproteins derived from the same, can be produced by a variety of methods.Recombinant products can take the form of partial protein sequences,full-length sequences, precursor forms that include signal sequences,mature forms without signals, or even fusion proteins (e.g., with anappropriate leader for the recombinant host, or with another subunitantigen sequence for another pathogen).

Gene libraries can be constructed and the resulting clones used totransform an appropriate host cell. Colonies can be pooled and screenedusing polyclonal serum or monoclonal antibodies to the PCVII protein.

Alternatively, once the amino acid sequences are determined,oligonucleotide probes which contain the codons for a portion of thedetermined amino acid sequences can be prepared and used to screengenomic or cDNA libraries for genes encoding the subject proteins. Thebasic strategies for preparing oligonucleotide probes and DNA libraries,as well as their screening by nucleic acid hybridization, are well knownto those of ordinary skill in the art. See, e.g., DNA Cloning: Vol. I,supra; Nucleic Acid Hybridization, supra; Oligonucleotide Synthesis,supra; Sambrook et al., supra. Once a clone from the screened libraryhas been identified by positive hybridization, it can be confirmed byrestriction enzyme analysis and DNA sequencing that the particularlibrary insert contains a PCVII protein gene or a homolog thereof. Thegenes can then be further isolated using standard techniques and, ifdesired, PCR approaches or restriction enzymes employed to deleteportions of the full-length sequence.

Similarly, genes can be isolated directly from viruses using knowntechniques, such as phenol extraction and the sequence furthermanipulated to produce any desired alterations. See, e.g., the examplesherein and Hamel et al. (1998) J. Virol. 72:5262-5267, for a descriptionof techniques used to obtain and isolate viral DNA.

Alternatively, DNA sequences can be prepared synthetically rather thancloned. The DNA sequences can be designed with the appropriate codonsfor the particular amino acid sequence if the sequences are to be usedin protein production. In general, one will select preferred codons forthe intended host if the sequence will be used for expression. Thecomplete sequence is assembled from overlapping oligonucleotidesprepared by standard methods and assembled into a complete codingsequence. See, e.g., Edge (1981) Nature 292:756; Nambair et al. (1984)Science 223:1299; Jay et al. (1984) J. Biol. Chem. 259:6311.

Once coding sequences for the desired proteins have been prepared orisolated, they can be cloned into any suitable vector or replicon.Numerous cloning vectors are known to those of skill in the art, and theselection of an appropriate cloning vector is a matter of choice.Examples of recombinant DNA vectors for cloning and host cells whichthey can transform include the bacteriophage .λ (E. coli), pBR322 (E.coli), pACYC177 (E. coli), pKT230 (gram-negative bacteria), pGV1106(gram-negative bacteria), pLAFR1 (gram-negative bacteria), pME290(non-E. coli gram-negative bacteria), pHV14 (E. coli and Bacillussubtilis), pBD9 (Bacillus), pIJ61 (Streptomyces), pUC6 (Streptomyces),YIp5 (Saccharomyces), YCp19 (Saccharomyces) and bovine papilloma virus(mammalian cells). See, Sambrook et al., supra; DNA Cloning, supra; B.Perbal, supra.

The gene can be placed under the control of a promoter, ribosome bindingsite (for bacterial expression) and, optionally, an operator(collectively referred to herein as “control” elements), so that the DNAsequence encoding the desired protein is transcribed into RNA in thehost cell transformed by a vector containing this expressionconstruction. The coding sequence may or may not contain a signalpeptide or leader sequence. If a signal sequence is included, it caneither be the native, homologous sequence, or a heterologous sequence.Leader sequences can be removed by the host in post-translationalprocessing. See, e.g., U.S. Pat. Nos. 4,431,739; 4,425,437; 4,338,397.

Other regulatory sequences may also be desirable which allow forregulation of expression of the protein sequences relative to the growthof the host cell. Regulatory sequences are known to those of skill inthe art, and examples include those which cause the expression of a geneto be turned on or off in response to a chemical or physical stimulus,including the presence of a regulatory compound. Other types ofregulatory elements may also be present in the vector, for example,enhancer sequences.

The control sequences and other regulatory sequences may be ligated tothe coding sequence prior to insertion into a vector, such as thecloning vectors described above. Alternatively, the coding sequence canbe cloned directly into an expression vector which already contains thecontrol sequences and an appropriate restriction site.

In some cases it may be necessary to modify the coding sequence so thatit may be attached to the control sequences with the appropriateorientation; i.e., to maintain the proper reading frame. It may also bedesirable to produce mutants or analogs of the desired PCVII protein.Mutants or analogs may be prepared by the deletion of a portion of thesequence encoding the protein, by insertion of a sequence, and/or bysubstitution of one or more nucleotides within the sequence. Techniquesfor modifying nucleotide sequences, such as site-directed mutagenesis,are described in, e.g., Sambrook et al., supra; DNA Cloning, supra;Nucleic Acid Hybridization, supra.

The expression vector is then used to transform an appropriate hostcell. A number of mammalian cell lines are known in the art and includeimmortalized cell lines available from the American Type CultureCollection (ATCC), such as, but not limited to, Chinese hamster ovary(CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidneycells (COS), human hepatocellular carcinoma cells (e.g., Hep G2),Madin-Darby bovine kidney (“MDBK”) cells, as well as others. Similarly,bacterial hosts such as E. coli, Bacillus subtilis, and Streptococcusspp., will find use with the present expression constructs. Yeast hostsuseful in the present invention include inter alia, Saccharomycescerevisiae, Candida albicans, Candida maltosa, Hansenula polymorpha,Kluyveromyces fragilis, Kluyveromyces lactis, Pichia guillerimondii,Pichia pastoris, Schizosaccharomyces pombe and Yarrowia lipolytica.Insect cells for use with baculovirus expression vectors include, interalia, Aedes aegypti, Autographa californica, Bombyx mori, Drosophilamelanogaster, Spodoptera frugiperda, and Trichoplusia ni.

Depending on the expression system and host selected, the proteins ofthe present invention are produced by culturing host cells transformedby an expression vector described above under conditions whereby theprotein of interest is expressed. The protein is then isolated from thehost cells and purified. If the expression system secretes the proteininto the growth media, the protein can be purified directly from themedia. If the protein is not secreted, it is isolated from cell lysates.The selection of the appropriate growth conditions and recovery methodsare within the skill of the art.

The proteins of the present invention may also be produced by chemicalsynthesis such as solid phase peptide synthesis, using known amino acidsequences or amino acid sequences derived from the DNA sequence of thegenes of interest. Such methods are known to those skilled in the art.See, e.g., J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis,2nd Ed., Pierce Chemical Co., Rockford, Ill. (1984) and G. Barany and R.B. Merrifield, The Peptides: Analysis, Synthesis, Biology, editors E.Gross and J. Meienhofer, Vol. 2, Academic Press, New York, (1980), pp.3-254, for solid phase peptide synthesis techniques; and M. Bodansky,Principles of Peptide Synthesis, Springer-Verlag, Berlin (1984) and E.Gross and J. Meienhofer, Eds., The Peptides: Analysis, Synthesis,Biology, supra, Vol. 1, for classical solution synthesis. Chemicalsynthesis of peptides may be preferable if a small fragment of theantigen in question is capable of raising an immunological response inthe subject of interest.

Analysis of the genome shows the presence of at least six open readingframes, at least one of which encodes the putative DNA replicase gene.

B.3. Preparation of Antigenic Polypeptides and Conjugation with Carrier

The antigenic region of peptides is generally relatively small—typically10 amino acids or less in length. Fragments of as few as 5 amino acidsmay typically characterize an antigenic region. Accordingly, using thegenome of PCVII as a basis, DNAs encoding short segments ofpolypeptides, derived from any of the various ORFs of PCVII, such asORFs 1-6, and particularly ORF 6, can be expressed recombinantly eitheras fusion proteins or as isolated peptides. In addition, short aminoacid sequences can be chemically synthesized. In instances wherein thesynthesized peptide is correctly configured so as to provide the correctepitope, but too small to be immunogenic, the peptide may be linked to asuitable carrier.

A number of techniques for obtaining such linkage are known in the art,including the formation of disulfide linkages usingN-succinimidyl-3-(2-pyridyl-thio)propionate (SPDP). and succinimidyl4-(N-maleimido-methyl)cyclohexane-1-carboxylate (SMCC) obtained fromPierce Company, Rockford, Ill. (If the peptide lacks a sulfhydryl, thiscan be provided by addition of a cysteine residue.) These reagentscreate a disulfide linkage between themselves and peptide cysteineresidues on one protein and an amide linkage through the e-amino on alysine, or other free amino group in the other. A variety of suchdisulfide/amide-forming agents are known. See, for example, Immun. Rev.(1982) 62:185. Other bifunctional coupling agents form a thioetherrather than a disulfide linkage. Many of these thioether-forming agentsare commercially available and include reactive esters of6-maleimidocaproic acid, 2-bromoacetic acid, 2-iodoacetic acid,4-(N-maleimido-methyl)cycloh-exane-1-carboxylic acid, and the like. Thecarboxyl groups can be activated by combining them with succinimide or1-hydroxy-2-nitro-4-sulfonic acid, sodium salt. The foregoing list isnot meant to exhaustive, and modifications of the named compounds canclearly be used.

Any carrier may be used, which does not itself induce the production ofantibodies harmful to the host, such as the various serum albumins,tetanus toxoids, or keyhole limpet hemocyanin (KLH).

The conjugates, when injected into suitable subjects, will result in theproduction of antisera which contain immunoglobulins specificallyreactive against not only the conjugates, but also against fusionproteins carrying the analogous portions of the sequence, and againstappropriate determinants within whole PCVII.

B.4. Production of Antibodies

Proteins encoded by the novel viruses of the present invention, or theirfragments, can be used to produce antibodies, both polyclonal andmonoclonal. If polyclonal antibodies are desired, a selected mammal,(e.g., mouse, rabbit, goat, horse, etc.) is immunized with an antigen ofthe present invention, or its fragment, or a mutated antigen. Serum fromthe immunized animal is collected and treated according to knownprocedures. See, e.g., Jurgens et al. (1985) J. Chrom. 348:363-370. Ifserum containing polyclonal antibodies is used, the polyclonalantibodies can be purified by immunoaffinity chromatography, using knownprocedures.

Monoclonal antibodies to the proteins and to the fragments thereof, canalso be readily produced by one skilled in the art. The generalmethodology for making monoclonal antibodies by using hybridomatechnology is well known. Immortal antibody-producing cell lines can becreated by cell fusion, and also by other techniques such as directtransformation of B lymphocytes with oncogenic DNA, or transfection withEpstein-Barr virus. See, e.g., M. Schreier et al., Hybridoma Techniques(1980); Hammerling et al., Monoclonal Antibodies and T-cell Hybridomas(1981); Kennett et al., Monoclonal Antibodies (1980); see also U.S. Pat.Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,452,570; 4,466,917;4,472,500, 4,491,632; and 4,493,890. Panels of monoclonal antibodiesproduced against the desired protein, or fragment thereof, can bescreened for various properties; i.e., for isotype, epitope, affinity,etc. Monoclonal antibodies are useful in purification, usingimmunoaffinity techniques, of the individual antigens which they aredirected against. Both polyclonal and monoclonal antibodies can also beused for passive immunization or can be combined with subunit vaccinepreparations to enhance the immune response. Polyclonal and monoclonalantibodies are also useful for diagnostic purposes.

B.5. Vaccine Formulations and Administration

The novel viral proteins of the present invention can be formulated intovaccine compositions, either alone or in combination with otherantigens, for use in immunizing subjects as described below. Methods ofpreparing such formulations are described in, e.g., Remington'sPharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 18Edition, 1990. Typically, the vaccines of the present invention areprepared as injectables, either as liquid solutions or suspensions.Solid forms suitable for solution in or suspension in liquid vehicle'sprior to injection may also be prepared. The preparation may also beemulsified or the active ingredient encapsulated in liposome vehicles.The active immunogenic ingredient is generally mixed with a compatiblepharmaceutical vehicle, such as, for example, water, saline, dextrose,glycerol, ethanol, or the like, and combinations thereof. In addition,if desired, the vehicle may contain minor amounts of auxiliarysubstances such as wetting or emulsifying agents and pH bufferingagents.

Adjuvants which enhance the effectiveness of the vaccine may also beadded to the formulation. Such adjuvants include, without limitation,adjuvants formed from aluminum salts (alum), such as aluminum hydroxide,aluminum phosphate, aluminum sulfate, etc; oil-in-water and water-in-oilemulsion formulations, such as Complete Freunds Adjuvant (CFA),Incomplete Freunds Adjuvant (IFA), avridine and dimethyldioctadecylammonium bromide (DDA); adjuvants formed from bacterial cell wallcomponents such as adjuvants including monophosphoryl lipid A (MPL)(Imoto et al. (1985) Tet. Lett. 26:1545-1548), trehalose dimycolate(TDM), and cell wall skeleton (CWS); adjuvants derived fromADP-ribosylating bacterial toxins, such as derived from diphtheria toxin(for example, CRM₁₉₇, a non-toxic diphtheria toxin mutant (see, e.g.,Bixler et al. (1989) Adv. Exp. Med. Biol. 251:175; and Constantino etal. (1992) Vaccine), pertussis toxin (PT), cholera toxin (CT), the E.coli heat-labile toxins (LT1 and LT2), Pseudomonas endotoxin A, C.botulinum C2 and C3 toxins, as well as toxins from C. perfringens, C.spiriforma and C. difficile; saponin adjuvants such as Quil A (U.S. Pat.No. 5,057,540), or particles generated from saponins such as ISCOMs(immunostimulating complexes); cytokines, such as interleukins (e.g.,IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (e.g.,gamma interferon), macrophage colony stimulating factor (M-CSF), tumornecrosis factor (TNF), etc; muramyl peptides such asN-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP),N-acetyl-normuramyl-^(L)-alanyl-^(D)-isoglutamine (nor-MDP),N-acetylmuramyl-^(L)-alanyl-^(D)-isoglutaminyl-^(L)-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3huydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.; adjuvants derived fromthe CpG family of molecules, CpG dinucleotides and syntheticoligonucleotides which comprise CpG motifs (see, e.g., Krieg et. al.Nature (1995) 374:546 and Davis et al. J. Immunol. (1998) 160:870-876);and synthetic adjuvants such as PCPP (Polydi(carboxylatophenoxy)phosphazene) (Payne et al. Vaccines (1998)16:92-98). Such adjuvants are commercially available from a number ofdistributors such as Accurate Chemicals; Ribi Immunechemicals, Hamilton,Mont.; GIBCO; Sigma, St. Louis, Mo.

As explained above, the proteins may be linked to a carrier in order toincrease the immunogenicity thereof. Suitable carriers include large,slowly metabolized macromolecules such as proteins, including serumalbumins, keyhole limpet hemocyanin, immunoglobulin molecules,thyroglobulin, ovalbumin, and other proteins well known to those skilledin the art; polysaccharides, such as sepharose, agarose, cellulose,cellulose beads and the like; polymeric amino acids such as polyglutamicacid, polylysine, and the like; amino acid copolymers; and inactivevirus particles.

The proteins may be used in their native form or their functional groupcontent may be modified by, for example, succinylation of lysineresidues or reaction with Cys-thiolactone. A sulfhydryl group may alsobe incorporated into the carrier (or antigen) by, for example, reactionof amino functions with 2-iminothiolane or the N-hydroxysuccinimideester of 3-(4-dithiopyridyl propionate. Suitable carriers may also bemodified to incorporate spacer arms (such as hexamethylene diamine orother bifunctional molecules of similar size) for attachment ofpeptides.

Other suitable carriers for the proteins of the present inventioninclude VP6 polypeptides of rotaviruses, or functional fragmentsthereof, as disclosed in U.S. Pat. No. 5,071,651, incorporated herein byreference. Also useful is a fusion product of a viral protein and thesubject inmunogens made by methods disclosed in U.S. Pat. No. 4,722,840.Still other suitable carriers include cells, such as lymphocytes, sincepresentation in this form mimics the natural mode of presentation in thesubject, which gives rise to the immunized state. Alternatively, theproteins of the present invention may be coupled to erythrocytes,preferably the subject's own erythrocytes. Methods of coupling peptidesto proteins or cells are known to those of skill in the art.

Furthermore, the proteins may be formulated into vaccine compositions ineither neutral or salt forms. Pharmaceutically acceptable salts includethe acid addition salts (formed with the free amino groups of the activepolypeptides) and which are formed with in-organic acids such as, forexample, hydrochloric or phosphoric acids, or such organic acids asacetic, oxalic, tartaric, mandelic, and the like. Salts formed from freecarboxyl groups may also be derived from inorganic bases such as, forexample, sodium, potassium, ammonium, calcium, or ferric hydroxides, andsuch organic bases as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, procaine, and the like.

Vaccine formulations will contain a “therapeutically effective amount”of the active ingredient, that is, an amount capable of eliciting animmune response in a subject to which the composition is administered.Such a response will be demonstrated by either a reduction or lack ofsymptoms normally displayed by an infected host and/or a quickerrecovery time.

The exact amount is readily determined by one skilled in the art usingstandard tests. The protein concentration will typically range fromabout 1% to about 95% (w/w) of the composition, or even higher or lowerif appropriate.

To immunize a subject, the vaccine is generally administeredparenterally, usually by intramuscular injection. Other modes ofadministration, however, such as subcutaneous, intraperitoneal andintravenous injection, are also acceptable. The quantity to beadministered depends on the animal to be treated, the capacity of theanimal's immune system to synthesize antibodies, and the degree ofprotection desired. Effective dosages can be readily established by oneof ordinary skill in the art through routine trials establishing doseresponse curves. The subject is immunized by administration of thevaccine in at least one dose, and preferably two doses. Moreover, theanimal may be administered as many doses as is required to maintain astate of immunity to infection.

Additional vaccine formulations which are suitable for other modes ofadministration include suppositories and, in some cases, aerosol,intranasal, oral formulations, and sustained release formulations. Forsuppositories, the vehicle composition will include traditional bindersand carriers, such as, polyalkaline glycols, or triglycerides. Suchsuppositories may be formed from mixtures containing the activeingredient in the range of about 0.5% to about 10% (w/w), preferablyabout 1% to about 2%. Oral vehicles include such normally employedexcipients as, for example, pharmaceutical grades of mannitol, lactose,starch, magnesium, stearate, sodium saccharin cellulose, magnesiumcarbonate, and the like. These oral vaccine compositions may be taken inthe form of solutions, suspensions, tablets, pills, capsules, sustainedrelease formulations, or powders, and contain from about 10% to about95% of the active ingredient, preferably about 25% to about 70%.

Intranasal formulations will usually include vehicles that neither causeirritation to the nasal mucosa nor significantly disturb ciliaryfunction. Diluents such as water, aqueous saline or other knownsubstances can be employed with the subject invention. The nasalformulations may also contain preservatives such as, but not limited to,chlorobutanol and benzalkonium chloride. A surfactant may be present toenhance absorption of the subject proteins by the nasal mucosa.

Controlled or sustained release formulations are made by incorporatingthe protein into carriers or vehicles such as liposomes, nonresorbableimpermeable polymers such as ethylenevinyl acetate copolymers andHytrel® copolymers, swellable polymers such as hydrogels, or resorbablepolymers such as collagen and certain polyacids or polyesters such asthose used to make resorbable sutures. The proteins can also bedelivered using implanted mini-pumps, well known in the art.

The proteins of the instant invention can also be administered via acarrier virus which expresses the same. Carrier viruses which will finduse with the instant invention include but are not limited to thevaccinia and other pox viruses, adenovirus, and herpes virus. By way ofexample, vaccinia virus recombinants expressing the novel proteins canbe constructed as follows. The DNA encoding the particular protein isfirst inserted into an appropriate vector so that it is adjacent to avaccinia promoter and flanking vaccinia DNA sequences, such as thesequence encoding thymidine kinase (TK). This vector is then used totransfect cells which are simultaneously infected with vaccinia.Homologous recombination serves to insert the vaccinia promoter plus thegene encoding the instant protein into the viral genome. The resultingTK recombinant can be selected by culturing the cells in the presence of5-bromodeoxyuridine and picking viral plaques resistant thereto.

An alternative route of administration involves gene therapy or nucleicacid immunization. Thus, nucleotide sequences (and accompanyingregulatory elements) encoding the subject proteins can be administereddirectly to a subject for in vivo translation thereof. Alternatively,gene transfer can be accomplished by transfecting the subject's cells ortissues ex vivo and reintroducing the transformed material into thehost. DNA can be directly introduced into the host organism, i.e., byinjection (see U.S. Pat. Nos. 5,580,859 and 5,589,466; InternationalPublication No. WO/90/11092; and Wolff et al. (1990) Science247:1465-1468). Liposome-mediated gene transfer can also be accomplishedusing known methods. See, e.g., U.S. Pat. No. 5,703,055; Hazinski et al.(1991) Am. J. Respir. Cell Mol. Biol. 4:206-209; Brigham et al. (1989)Am. J. Med. Sci. 298:278-281; Canonico et al. (1991) Clin. Res. 39:219A;and Nabel et al. (1990) Science 249:1285-1288. Targeting agents, such asantibodies directed against surface antigens expressed on specific celltypes, can be covalently conjugated to the liposomal surface so that thenucleic acid can be delivered to specific tissues and cells susceptibleto infection.

B.6. Diagnostic Assays

As explained above, the proteins of the present invention may also beused as diagnostics to detect the presence of reactive antibodies ofPCVII in a biological sample in order to determine the presence of PCVIIinfection. For example, the presence of antibodies reactive with theproteins can be detected using standard electrophoretic andimmunodiagnostic techniques, including immunoassays such as competition,direct reaction, or sandwich type assays. Such assays include, but arenot limited to, Western blots; agglutination tests; enzyme-labeled andmediated immunoassays, such as ELISAs; biotin/avidin type assays;radioimmunoassays; immunoelectrophoresis; immunoprecipitation, etc. Thereactions generally include revealing labels such as fluorescent,chemiluminescent, radioactive, enzymatic labels or dye molecules, orother methods for detecting the formation of a complex between theantigen and the antibody or antibodies reacted therewith.

The aforementioned assays generally involve separation of unboundantibody in a liquid phase from a solid phase support to whichantigen-antibody complexes are bound. Solid supports which can be usedin the practice of the invention include substrates such asnitrocellulose (e.g., in membrane or microtiter well form);polyvinylchloride (e.g., sheets or microtiter wells); polystyrene latex(e.g., beads or microtiter plates); polyvinylidine fluoride; diazotizedpaper; nylon membranes; activated beads, magnetically responsive beads,and the like.

Typically, a solid support is first reacted with a solid phase component(e.g., one or more PCVII proteins) under suitable binding conditionssuch that the component is sufficiently immobilized to the support.Sometimes, immobilization of the antigen to the support can be enhancedby first coupling the antigen to a protein with better bindingproperties. Suitable coupling proteins include, but are not limited to,macromolecules such as serum albumins including bovine serum albumin(BSA), keyhole limpet hemocyanin, immunoglobulin molecules,thyroglobulin, ovalbumin, and other proteins well known to those skilledin the art. Other molecules that can be used to bind the antigens to thesupport include polysaccharides, polylactic acids, polyglycolic acids,polymeric amino acids, amino acid copolymers, and the like. Suchmolecules and methods of coupling these molecules to the antigens, arewell known to those of ordinary skill in the art. See, e.g., Brinkley,M. A. Bioconjugate Chem. (1992) 3:2-13; Hashida et al., J. Appl.Biochem. (1984) 6:56-63; and Anjaneyulu and Staros, International J. ofPeptide and Protein Res. (1987) 30:117-124.

After reacting the solid support with the solid phase component, anynon-immobilized solid-phase components are removed from the support bywashing, and the support-bound component is then contacted with abiological sample suspected of containing ligand moieties (e.g.,antibodies toward the immobilized antigens) under suitable bindingconditions. After washing to remove any non-bound ligand, a secondarybinder moiety is added under suitable binding conditions, wherein thesecondary binder is capable of associating selectively with the boundligand. The presence of the secondary binder can then be detected usingtechniques well known in the art.

Mote particularly, an ELISA method can be used, wherein the wells of amicrotiter plate are coated with a desired protein. A biological samplecontaining or suspected of containing anti-protein immunoglobulinmolecules is then added to the coated wells. After a period ofincubation sufficient to allow antibody binding to the immobilizedantigen, the plate(s) can be washed to remove unbound moieties and adetectably labeled secondary binding molecule added. The secondarybinding molecule is allowed to react with any captured sampleantibodies, the plate washed and the presence of the secondary bindingmolecule detected using methods well known in the art.

Thus, in one particular embodiment, the presence of bound anti-antigenligands from a biological sample can be readily detected using asecondary binder comprising an antibody directed against the antibodyligands. A number of anti-porcine immunoglobulin (Ig) molecules areknown in the art which can be readily conjugated to a detectable enzymelabel, such as horseradish peroxidase, alkaline phosphatase or urease,using methods known to those of skill in the art. An appropriate enzymesubstrate is then used to generate a detectable signal. In other relatedembodiments, competitive-type ELISA techniques can be practiced usingmethods known to those skilled in the art.

Assays can also be conducted in solution, such that the proteins andantibodies specific for those proteins form complexes underprecipitating conditions. In one particular embodiment, proteins can beattached to a solid phase particle (e.g., an agarose bead or the like)using coupling techniques known in the art, such as by direct chemicalor indirect coupling. The antigen-coated particle is then contactedunder suitable binding conditions with a biological sample suspected ofcontaining antibodies for the proteins. Cross-linking between boundantibodies causes the formation of particle-antigen-antibody complexaggregates which can be precipitated and separated from the sample usingwashing and/or centrifugation. The reaction mixture can be analyzed todetermine the presence or absence of antibody-antigen complexes usingany of a number of standard methods, such as those immunodiagnosticmethods described above.

In yet a further embodiment, an immunoaffinity matrix can be provided,wherein a polyclonal population of antibodies from a biological samplesuspected of containing antibodies to the protein of interest isimmobilized to a substrate. In this regard, an initial affinitypurification of the sample can be carried out using immobilizedantigens. The resultant sample preparation will thus only containanti-PCVII moieties, avoiding potential nonspecific binding propertiesin the affinity support. A number of methods of immobilizingimmunoglobulins (either intact or in specific fragments) at high yieldand good retention of antigen binding activity are known in the art. Notbeing limited by any particular method, immobilized protein A or proteinG can be used to immobilize immunoglobulins.

Accordingly, once the immunoglobulin molecules have been immobilized toprovide an immunoaffinity matrix, labeled proteins are contacted withthe bound antibodies under suitable binding conditions. After anynon-specifically bound antigen has been washed from the immunoaffinitysupport, the presence of bound antigen can be determined by assaying forlabel using methods known in the art.

Additionally, antibodies raised to the proteins, rather than theproteins themselves, can be used in the above-described assays in orderto detect the presence of antibodies to the proteins in a given sample.These assays are performed essentially as described above and are wellknown to those of skill in the art.

Furthermore, nucleic acid-based assays may also be conducted. In thisregard, using the disclosed PCVII nucleic acid sequences as a basis,oligomers can be prepared which are useful as hybridization probes orPCR primers to detect the presence of the viral genome in, for example,biological samples from subjects suspected of harboring the virus.Oligomers for use in this embodiment of the invention are approximately8 nucleotides or more in length, preferably at least about 10-12nucleotides in length, more preferably at least about 15 to 20nucleotides in length and up to 50 or more nucleotides in length.Preferably, the oligomers derive from regions of the viral genome whichlack heterogeneity.

The oligomers are prepared either by excision from the genome, orrecombinantly or synthetically. For example, the oligomers can beprepared using routine methods, such automated oligonucleotide syntheticmethods.

The oligomers may be used as probes in diagnostic assays. In arepresentative assay, the biological sample to be analyzed is treated toextract the nucleic acids contained therein. The resulting nucleic acidfrom the sample may be subjected to gel electrophoresis or other sizeseparation techniques. Alternatively, the nucleic acid sample may bedot-blotted without size separation. The probes are then labeled with areporter moiety. Suitable labels, and methods for labeling probes, areknown in the art and include, for example, radioactive labelsincorporated by nick translation or kinasing, biotin, fluorescent probesand chemiluminescent probes. The nucleic acids extracted from the sampleare then treated with the labeled probe under hybridization conditionsof suitable stringencies.

The probes can be made completely complementary to the targeted PCVIIgene sequence. However, when longer probes are used in the diagnosticassays, the amount of complementarity may be less. Generally, conditionsof high stringency are used in the assay methods, especially if theprobes are completely or highly complementary. However, lower stringencyconditions should be used when targeting regions of heterogeneity.Methods of adjusting stringency are well known in the art. Suchadjustments are made during hybridization and the washing procedure andinclude adjustments to temperature, ionic strength, concentration offormamide and length of time of the reaction. These factors are outlinedin, e.g., Sambrook et al., supra.

In a more specific embodiment, the above-described method includes theuse of PCVII nucleic acid specific probes where two probes (primers)define an internal region of the PCVII genome. In this embodiment, eachprobe has one strand containing a 3′-end internal to the PCVII nucleicacid internal region. The nucleic acid/probe hybridization complexes arethen converted to double-strand probe containing fragments by primerextension reactions. Probe-containing fragments are amplified bysuccessively repeating the steps of (i) denaturing the double-strandedfragments to produce single-stranded fragments, (ii) hybridizing thesingle strands with the probes to form strand/probe complexes, (iii)generating double-stranded fragments from the strand/probe complexes inthe presence of DNA polymerase and all four deoxyribonucleotides, and(iv) repeating steps (i) to (iii) until a desired degree ofamplification has been achieved. Amplification products are thenidentified according to established procedures. The method of theinvention may further include a third polynucleotide probe capable ofselectively hybridizing to the internal region described above but notto the specific probe/primer sequences used for amplification.

PCR techniques, such as those described above, are well known in theart. See, e.g., PCR Protocols: A Guide to Methods and Applications(Academic Press); PCR A Practical Approach (IRL press); Saiki et al.(1986) Nature 324:163.

Other amplification methods can also be used in the nucleic acid-basedassays, such as ligase chain reaction (LCR), PCR, Q-beta replicase, andthe like.

Other assays for use herein include the “Bio-Bridge” system which usesterminal deoxynucleotide transferase to add unmodified 3′-poly-dT-tailsto a nucleic acid probe (Enzo Biochem. Corp.). The poly dt-tailed probeis hybridized to the target nucleotide sequence, and then to abiotin-modified poly-A. Additionally, EP 124221 describes a DNAhybridizationassay wherein the analyte is annealed to a single-strandedDNA probe that is complementary to an enzyme-labelled oligonucleotide,and the resulting tailed duplex is hybridized to an enzyme-labelledoligonucleotide. EP 204510 describes a DNA hybridization assay in whichanalyte DNA is contacted with a probe that has a tail, such as apoly-dT-tail, an amplifier strand that has a sequence that hybridizes tothe tail of the probe, such as a poly-A sequence, and which is capableof binding a plurality of labelled strands. The technique first mayinvolve amplification of the target PCVII sequences in sera toapproximately 10⁶ sequences/ml, as described above. The amplifiedsequence(s) then may be detected using a hybridization assay known inthe art.

Furthermore, nucleic acid sequences derived from the PCVII viral genome,may also be used for in situ hybridization assays. Generally, suchassays employ formalin-fixed cell culture preparations or tissues, suchas lymph node, spleen, tonsil, liver, lung, heart, kidney, pancreas,nasal turbinate, large and small intestine, and the like. See, e.g.,Sirinarumitr et al. (1996) J. Virol. Meth. 56:149-160, for a descriptionof a suitable in situ hybridization assay.

The above-described assay reagents, including the proteins, antibodiesthereto or oligomers, can be provided in kits, with suitableinstructions and other necessary reagents, in order to conductimmunoassays as described above. The kit can also contain, depending onthe particular immunoassay used, suitable labels and other packagedreagents and materials (i.e. wash buffers and the like). Standardimmunoassays, such as those described above, can be conducted usingthese kits.

Below are examples of specific embodiments for carrying out the presentinvention. The examples are offered for illustrative purposes only, andare not intended to limit the scope of the present invention in any way.

C. Experimental

Materials and Methods

Cell Cultures

The Dulac cell line, a PCV-free PK15 derivative, was obtained from Dr.John Ellis (University of Saskatchewan, Saskatoon, Saskatchewan). TheVero cell line was obtained from American Type Culture Collection(ATCC), Manassas, Va. These cells were cultured in media suggested bythe ATCC and incubated at 37° C. with 5% CO₂.

Porcine Circoviruses

The classic PCVI was isolated from persistently infected PK15 cells(ATCC CCL33). Isolate PCVII 412 was obtained from lymph nodes of apiglet challenged with the lymph node homogenate from PMWS-affectedpiglets. This challenged piglet had been diagnosed with PMWS. IsolatePCVII 9741 was isolated from the buffy-coat of peripheral blood from aPMWS-affected piglet of the same herd after the isolation of PCVII 412.Isolate PCVII B9 was isolated from an affected piglet in a United Statesswine herd with a PMWS clinical outbreak in the fall of 1997.

Propagation of PCVI

PCVI from persistently infected PK15 cells was grown and purified usinga modified method of Tischer et al (1987) Arch. Virol. 96:39-57.Briefly, PCV harvested from PK15 cells was used to super-infect amonolayer of PK15 cells at about 1 moi for two hours before the cellswere treated with 300 mM D-glucosamine. After washing the cells once,DMEM (Gibco, catalog number 21013) with 5% FBS was added to the cellsand the cells were incubated for an additional four days. The infectedcells were scraped off and collected after centrifugation at 1500×g for15 minutes. The cell pellet was then treated with 0.5% of Triton X-114at 37° C. for 30 minutes. After another low speed centrifugation toremove cellular debris, an equal amount of Freon (Sigma catalog numberT-5271) was added to the supernatant and the mixture was homogenized forone minute using a Polytron at maximum speed. The mixture was thencentrifuged and the top layer collected and mixed with an equal volumeof 0.1 M PBS. The virus pellet was collected after ultra centrifugationinto a 20% sucrose cushion at 210,000×g for 30 minutes.

Culture of the Field Isolates (PCVII)

The isolate PCVII 412 was cultured and purified in a similar manner asPCVI, except Dulac cells were used. The isolate PCVII B9 was grown inheterogenic Vero cells transfected with self-ligated full-length PCRproducts from the United States PMWS outbreak. Therefore, thepossibility of contamination from other pig pathogens was eliminated.The B9-transfected Vero cells were continuously passed and treated with300 mM D-glucosamine as described above.

Viral DNA Isolation

Viral DNA was extracted from variable sources, including pellets ofinfected Dulac and Vero cells, peripheral blood buffy-coat cells,tissues from infected animals and serum. The tissue samples were treatedwith proteinase K and viral DNA was extracted using eitherphenol/chloroform or Qiagen tissue kit (Qiagen, Santa Clarita, Calif.).DNA from peripheral blood buffy coat cells of heparinized blood andserum was similarly collected using the Qiagen blood kit.

Infection of Piglets

Piglets were derived from specific pathogen-free sows. At one day ofage, each piglet received approximately one gram of lymph nodescollected from PMWS-affected piglets. The tissue homogenate wasdistributed equally between the oral and intraperitoneal routes. Tenpiglets were used in each of the experimental groups and observed dailyfor 7 weeks. Two groups were challenged and 2 were uninfected controls.Two groups, one challenged and one control, were also treated withcyclosporin A (2 mg/kg) at Day 0 and Day 14. The piglets were fed cannedmilk (Carnation) and water (50:50) until they self-weaned to highnutrient density commercially prepared feed.

PCR, Cloning and Sequencing of the Field PCV Isolates

A two-step approach was used for the initial cloning of isolate PCVII412 viral genomic DNA. A primer that hybridized to the conserved loopstem sequences, Loop (Table 1), was designed to perform a single-primedPCR taking advantage of the complementary sequences and the circularnature of PCV genomic DNA. The PCR reaction for the single-primed PCRwas a two-stage process. The first stage consisted of 5 cycles ofdenaturing at 94° C. for 1 minute, annealing at 37° C. for 30 secondsand extension at 72° C. for 2 minutes. The second stage consisted of 25cycles of a similar program except the annealing temperature wasincreased to 52° C. The PCR products were cloned into a TA cloningvector (Invitrogen, Carlsbad, Calif.). Both strands of three differentclones were sequenced to ensure sequence fidelity. Based on thesequences obtained, primer 1000− and R1F were designed in the noncodingregion of the viral DNA sequences and used to clone the full-lengthviral genome. The sequences of all the primers used in this study areshown in Table 1. The sequences of the loop region were then obtainedfrom the full-length clone. Sequences of isolate PCVII 9741 and PCVII B9were obtained from purified PCR products. Automated DNA sequencingperformed by Plant Biotechnology Institute of NRC, Canada was used withseveral internal primers. The sequences of isolates PCVII 412(AF085695), PCVII 9741 (AF086835) and PCVII B9 (AF086834) have beendeposited with the National Center for Biotechnology Information (NCBI).TABLE 1 Sequences of Primers Used in the Studies SEQ ID Primer NamePrimer Sequence NO: Loop ACTACAGCAGCGCACTTC 13 1000−AAAAAAGACTCAGTAATTTATTTCATATGG 14 R1F ATCACTTCGTAATGGTTTTTATT 15 1710+TGCGGTAACGCCTCCTTG 16 850− CTACAGCTGGGACAGCAGTTG 17 1100+CATACATGGTTACACGGATATTG 18 1570− CCGCACCTTCGGATATACTG 19 1230−TCCCGTTACTTCACACCCAA 22 400+ CCTGTCTACTGCTGTGAGTA 23Sequence Analyses

The sequences of other circoviruses were obtained from NCBI. Variouspublic domains were used for the sequence analysis, such as Biologyworkbench, Blast search, DNA/protein analysis tools, etc. The sequencealignments were generated using Clustal W program and phylogenetic treeswere created by PAUP 3.1 program (David L. Swofford, Laboratory ofMolecular Systematics, MRC534, MRC at Smithsonian Institution,Washington, D.C.).

Multiplex PCR

Two sets of primers were designed to identify the PCV group-specificsequences and strain-specific sequences. The primer pair 1710+/850− isPCV-group specific and 1100+/1570− is the novel PCV strain-specificpair, which differentiates the novel PCV from the one derived from PK15cells. The two sets of primers have similar annealing temperatures forthe PCR reaction and were used together at 0.5 μM concentration in astandard hot start PCR reaction. Either Ampli Taq Gold (Perkin Elmer) orPlentinum Taq (Gibco) was used.

Antiserum

The standard Berlin rabbit anti-PCVI antibody was kindly provided by Dr.Tischer (Koch Institute, Berlin, FRG). Rabbit anti-PCVII 412 pooledserum was obtained from two rabbits injected with purified isolate PCVII412 at 50 μg/dose in an oil-in-water emulsion. The injection wasrepeated 3 times at 21-day intervals. Pig anti-PMWS serum was collectedfrom convalescent pigs from PMWS affected herds.

ELISA

Purified PCV was diluted in sodium carbonate buffer (0.05 M) pH 9.6 to aconcentration of 0.5 μg per 100 μL and used to coat Immulon II plates(Dynatech Laboratories, Inc.). The plates were washed six times withTTBS (20 mM Tris-HCl, 500 mM NaCl, 0.05% of Tween 20, pH 7.5) beforeserially diluted primary rabbit or pig antibody was added. After sixwashes with TTBS, alkaline phosphatase-conjugated secondary antibodies (1/5000 dilution), either anti-rabbit or anti-pig (Kirkegaard & Perry),were added. Plates were developed with 100 μL/well of p-NitrophenylPhosphate (PNPP, 3 g/L) in 1 M diethanolamine, 0.5 MgCl₂, pH 9.8 and theplates were read on an ELISA reader (BioRad) at 405/490 mn.

FACS Analysis of Lymphocyte Surface Markers

Blood samples were collected from PMWS affected piglets in the field andnegative control. The RBC was lysed and WBC was stained with anti-pigCD3, CD4 and CD8 monoclonal antibodies, and followed by fluorescencelabeled anti-mouse secondary antibody. The specifically labeled cellswere fixed with 2% formaldehyde and 5000 cells were counted using FACSsystem (Becton Dickinson).

The present invention will now be more fully described with reference tothe following non-limiting Examples.

EXAMPLES Example 1 PMWS Reproduction

PMWS has not been reproduced under controlled conditions, nor haveetiology studies been performed. In order to determine the causativeagent of this disease, a number of tissues were collected fromPMWS-affected pigs, as described above in Materials and Methods, andstudied. Lymph nodes displayed the most apparent gross lesions,histopathological changes and circovirus infection was confirmed byimmunostaining. Accordingly, the lymph nodes were used in the challengeexperiments described above.

The challenge experiments, conducted as described in Materials andMethods were successful in producing PMWS in pigs. In particular, somepiglets died of the infection and asymptomatically infected pigletsdeveloped PMWS-like microscopic lesions by the end of the trial.

In another challenge experiment, the starting material used was lungtissue of pig with chronic wasting and lymph node enlargement. Theseclinical signs are characteristic of PMWS. The tissue was combined withsterile 0.1 M phosphate-buffered saline (PBS) and homogenized by passagethrough a polytron mixer. The crude tissue homogenate was used tochallenge pigs. In particular, a total of 40 piglets (approximately 1day of age) were randomly (balanced by litter of birth, gender and bodyweight) assigned to “tissue challenge,” “tissue challenge withCyclosporin-A,” “control,” or “Cyclosporin-A” treatment groups. Thecyclosporin treatment had no clinical or hematological effect on thetreated pigs except that cyclosporin was detected in the blood of thosepigs three hours after the drug was administered. Hence, groups werecollapsed across cyclosporin treatment for analysis.

In general, postmortem signs of PMWS disease in the challenged pigsincluded enlarged lymph nodes and incomplete collapse of lung tissue.Postmortem signs of PMWS disease were detected in significantly (p<0.01;two-tailed Fishers exact-test) more pigs in the group treated withtissue extract (7 pigs out of 9) than in the group treated with placebo(2 pigs out of 18). The average daily gain in the group treated byinjection of tissue extract (212 g/d) was not substantially differentfrom the group given the placebo (202 g/d).

Blood samples were obtained throughout the experiment and tissue sampleswere taken postmortem. The samples were tested for PCVII viral DNA byPCR, using PCR primers 1230− and 400+ (Table 1) which resulted in an 830base pair product. Four of the pigs given the lung tissue extract hadpositive blood samples; whereas none of the pigs given placebo had PCVIIDNA detected in their blood. PCVII was detected in one or more tissuesfrom 7 of the 8 surviving pigs in the “virus challenge” treatment groupwhereas all tissues from pigs in the control group were negative forPCVII. Contingency table analysis showed a significant difference(p<0.001; two-tailed Fishers exact-test).

In another challenge experiment, lung tissue of pig with chronic wastingand lymph node enlargement was collected and tissue debris removed bycentrifugation (8000 rpm for 30 minutes). The supernatant was applied toa cesium chloride step-gradient and centrifuged at 100,00×g. Bandsappeared between 41% CsCl₂ (1.28 gm/ml) and 63% (1.40 gm/ml). Thesebands were applied to a 30% CsCl₂ “foot” and centrifuged for 2 hours at100,000×g. The pellet was resuspended in 15 mL of sterile 0.1 M PBS.

A total of 20 weaned piglets (approximately three weeks of age) wererandomly (balanced by litter of birth, gender and body weight) assignedto “control” or “virus challenge” treatment groups. Pigs were weaned onDay 0 at approximately three weeks of age. In general, clinical signs ofPMWS disease included enlarged lymph nodes and wasting or poor growth.Enlarged lymph nodes were detected in significantly (p<0.02; two-tailedFisher exact-test) more pigs in the group treated with virus (7 pigs)than in the group treated with placebo (1 pig). The average daily gainin the group treated by virus injection (580 gm/d) tended to be lessthan the group given the placebo (616 gm/d), but the difference was notsignificant (p=0.17; two-tailed paired t-Test). There was no differencebetween groups in the relative mass of internal organs (liver, lung,heart, spleen, kidneys).

Blood samples that were obtained throughout the experiment and tissuesamples that were taken postmortem were tested for PCVII viral DNA usingthe PCR techniques described above.

All blood samples including those taken just prior to euthanasia werenegative for PCVII. PCVII was detected in one or more tissues for 8 ofthe 10 pigs in the “virus challenge” treatment group whereas all testedtissues from pigs in the control group were negative for PCVII.Contingency table analysis showed that this was a significant difference(p<0.001; two-tailed Fishers exact-test).

In conclusion, these experiments confirm that injection of weanedpiglets with tissue extracts and gradient-purified viral materialcontaining PCVII results in infection of multiple tissues. The infectionpersists for a duration of at least eight weeks.

Example 2 Isolation and Propagation of PCVII

To determine the presence of an infectious causative agent(s) for PMWS,various tissues from pig #412, an experimentally challenged pigletsacrificed 21 days post-infection, were used for viral isolation. Aftercontinued passage of lymph node samples from pig #412 in Dulac cells,virus accumulation or adaptation was observed. A unique pattern ofcytopathic effect initially developed, followed by increasing virustiter, as determined by ELISA using the standard Berlin anti-PCVantibody, as described above.

The existence of circovirus in Dulac cells infected with isolate PCVII412 was then detected by electron microscopic examination. After sixpassages, viral structure proteins could be detected consistently, usinga western blot assay.

Example 3 Specific Anti-PCVII Antibodies in Asymptomatically Infectedand Convalescent Piglets in PMWS-Affected Herds

Because it appeared that porcine circoviruses possessed someheterogeneity, ELISAs were performed using sera of piglets, collectedfrom a herd with a PMWS outbreak, against the PCV and isolate PCVII 412virus. Most of the asymptomatically PCVII-infected and convalescentpiglets developed specific antibodies against PCVII, not PCVI.

Example 4 Isolation, Cloning and Sequencing of PCVII Virus and ViralGenomic DNA

In order to explore genetic differences between the two strains ofporcine circoviruses, viral DNA was extracted from infected Dulac cells.Considering the possible genetic unrelatedness between PCVI and PCVII,the approach was to design primer(s) from the most conserved region.Previous analysis of the PK15 PCV DNA sequences (Mankertz et al. (1997)J. Gen. Virol. 71:2562-2566; Meehan et al. (1997) J. Gen. Virol.78:221-227) revealed a stem loop structure in the origin of replication.A single primer, targeting the inverted repeat sequence of the stem loopregion, Loop, was designed because of the highly conserved nature ofthis important domain. The amplification of the PCVII 412 viral DNA bysingle primer PCR was successful. After cloning into a TA cloningvector, the viral genomic sequence was obtained by automated sequencingfrom several clones and both senses to ensure fidelity. The actualsequence of the stem loop or primer region was then obtained from asecond full-length clone generated by primers of 1000− and R1F from theonly non-coding region of the virus. The nucleotide sequence for PMWS412 is shown in the top line of FIGS. 2A-2C.

Using similar primers, other PCVII isolates, including PCVII 9741 fromthe same herd as PCVII 412, and PCVII B9 from a PMWS outbreak in theUnited States, were obtained. These strains were sequenced and comparedto PCVII 412 and PCVI. See FIGS. 2A-2C for a comparison of PCVII 412with PCVI and FIGS. 4A-4B for comparisons of the PCVII 412 sequence withthe various PCV isolates.

The results of a phylogenetic analysis using the PAUP 3.1 programsuggested that the new PMWS isolates were closely related and in adifferent cluster with PCVI. These isolates were therefore termed“PCVII” isolates. The percent nucleotide sequence homologies amongisolates of the novel porcine circovirus were more than 99% identical.In contrast, comparison of these nucleotide sequences with the PK15 PCVIshowed only 75.8% overall nucleotide sequence homology. Comparativeanalysis of nucleotide sequences in different regions further revealedthat the putative replication-associated protein gene of these twoviruses share 81.4% homology, while the nucleotide sequences of theother large ORF was only 67.6% homologous.

Furthermore, nucleotide insertions and deletions (indels) were found inthree regions. There are 13 base insertions in the new isolates betweenPCVI sequence 38-61 that flank the start codon for the putative 35.8 kdprotein encoded by ORF 1. The area of PCVI 915-1033, containing 15 baseindels, was at the ends and the joint region of the two largest ORFs(the other ORF was antisense) of the porcine circoviruses. The thirdregion, covering PCVI sequence from 1529-1735 with 15 base indels,locates at the amino end of a putative 27.8 kd protein encoded by ORF 6.PCVI sequences were also compared with the available sequences of therest of the members of Circoviridae. PCVI is more closely related tobanana bunch top virus (BBTV), a plant virus, than to chicken anemiavirus (CAV) and beak and feather disease virus (BFDV) (both of which areavian circoviruses).

The gene map of isolate PCVII 412 is shown in FIG. 1. There are a totalof six potential ORFs encoding proteins larger than 50 amino acidresidues. A comparison between PCVII 412 and PK15 PCVI revealedhomologies in four of the ORFs (Table 2). The function of the 35.8 kd,namely the putative DNA replicase protein, has been previously predicted(Meehan et al. (1997) J. Gen. Virol. 78:221-227). Analysis of theseproteins predicted that both of the 35.8 kd and the antisense 27.8 kdproteins are nuclear proteins. Nucleotide sequence analysis alsoindicated that the start codons for the two proteins are within 33 basesof the origin of replication, which could also be the promoter. Inaddition, both ORFs ended with legitimate stop codons and poly A tailsignals. Since some of the predicted proteins (based on size) could befound in western blots, these findings suggest that porcine circoviralmRNA can be transcribed from both senses of the replicated forms.However, there is no coding sequence long enough to code for the common31 kd protein and the additional 20 kd protein for the PCVII 412 isolatedetected by western blot analysis. This suggests that post-translationalcleavage and/or RNA splicing may be involved in the expression of someof the porcine circovirus proteins. TABLE 2 Putative Amino Acid SequenceComparison Between PK15 PCVI and PCVII 412 Open reading frames SequenceHomology Predicted Localization PCVI 412 % PCVI/412 and Function 47-98351-992 83.5 Nucleus, putative (ORF 1) (ORF 1) Rep protein 1723-10241735-1037 66.4 Nucleus (ORF 6) (ORF 6) 552-207 565-389 40.9 EndoplasmicReticulum (ORF 4) (ORF 3) 658-40 671-359 29.1 Microbody (ORF 3) (ORF 2)

Example 5 Purification of PCVII Using Molecular Cloning Method

Dulac cells were found to be infected with porcine retrovirus which isalso found in many pig origin cell lines. In addition, other porcinepathogens were also found inconsistently associated with PCVII inPMWS-affected piglets. Thus, to obtain pure PCVII cultures, geneticallycloned PCVII DNA was transferred to the susceptible non-porcine originVero cells using liposomes. After two passages, amplified PCV antigenswere detected in the cells. The PCVII was seen to replicate andaccumulate in the nuclei and was released into cytoplasm and other cellsduring cell mitosis.

Example 6 Multiplex PCR in PCVII Identification and PMWS Diagnosis

In order to differentiate the two strains of porcine circoviruses, PCVIand PCVII, two sets of primers were designed based upon the comparativeanalysis of the viral DNA sequences. The PCV group-specific pair of1710+/850, and isolate PCVII 412 strain-specific 1100+/1570−, were usedin multiplex. PCR for testing field samples. These primer sets were usedwith frozen tissues and buffy coat cells of peripheral blood. As judgedby the multiplex PCR, using those primer sets, not only was PCVIIinfection identified in these samples but the genetic relatedness of thefield samples was also determined. The presence of circovirus was laterconfirmed by electron microscopy.

The potency of this diagnostic method was further tested with anothergroup of samples collected from a PMWS-affected herd (see FIG. 5). ThePCVII DNA sequences could also be identified in almost all the tissuesin PMWS-affected piglets (FIG. 6).

Example 7 PCVII Viremia Prior to and During PMWS Outbreak

The development of PCR using serum enabled us to test the PCVII viremiain a swineherd showing specific anti-PCVII antibody. A group of 23piglets was monitored from the age of one day until seven weeks andsamples were collected at approximately two week intervals. Afull-course of PCVII viremia and PMWS outbreak were observed, asindicated by the appearance to disappearance of the PCVII viremia whichwas detected in 9 of the 23 piglets. Most of piglets which showed PCVIIviremia developed PMWS with some exhibiting severe PMWS. Table 3 showsthe manifestation of PMWS in a typical pig. Gross lesions were found inmost organs and tissues (Table 3). TABLE 3 Clinical, Histological,VIrological and Immunological Report of a Typical PMWS Affected PigletPMWS Pig Gross appearance Histopath PCR H254 Spine, hairy, disinterestedand wobbled Saliva ND ND ND Urine Pale/clear ND + Bile Thin, not viscidND + Feces Scant but normal ND + Serum Normal ND + Plasma Yellow ND +Skin Hint of yellow + Fat Little/no fat + Muscle Normal + Tongue NormalGlossitis + Tonsil Small crypts Lymphocyte depletion + Cerv. LN EnlargedLymphocyte depletion + Med. LN Very large, dark surface, yellow centerLymphocyte depletion + Mesenteric LN Very enlarged, dark and wetLymphocyte depletion + Inguinal LN Large, dark and wet Lymphocytedepletion + Spleen Small and thin Lymphocyte depletion + Thymus Smalland difficult to find ND + Treachea Normal Metaplasia adenitis + Lung A,M lobes 80% atelectasis; firm texture Interstitial Pneumonia + mottlesand spots thoughout all lobes Heart Thin and flabby + Liver “Camouflage”pattern mottling + Gall Bladder Normal, moderately full + PancreasNormal + Adrenal Normal Focal adrenalitis + Brain Normal Meningitis +Eye Normal, white sclera + Stomach Normal, full of feed + Smallintestine Normal Peyers Patch + Large intestine Normal, sandy/grittycontents Submucosal inflam + Kidney Enlarged, dark and no pusInterstitial nephritis + Urinary bladder Normal + Ref mg × 10⁹/L CBCWBC: 20.1 11.0-22.0 Segs: 62% or 12.462 3.08-10.4 Lymphs: 29.0% or 5.8294.29-13.6 FACS CD3: 52.1% 55% CD4: 9.0% 30% CD8: 66.5% 15%

Example 8 Host Immune System Dysfunction in PMWS Affected Piglets

It is interesting that while lymphocyte infiltration was discovered inmost of the tissues, lymphocyte depletion was consistently found in allthe lymphoid tissues (Table 3). Decreased CD4 cell, and increased CD8cells were also seen, while CD3 cells remained relatively stable (Table4, mean numbers are from two PMWS affected and 40 negative controlpiglets). These changes resulted in CD4/CD8 ratio which drasticallydropped from 1.58 to 0.13. These finding suggested that PCVII couldinduce host immune system malfunction and therefore suppress the hostimmune responses to PCVII and possibly other pathogens. Thus, PMWSappears to be a disease of immunodeficiency in piglets. TABLE 4Lymphocyte Surface Markers of PMWS Affected and Control 6-week-oldPiglets CD3 CD4 CD8 CD4/CD8 Ratio PMWS 59.88 8.85 67.6 0.13 Control53.46 24.02 15.18 1.58Deposits of Strains Useful in Practicing the Invention

A deposit of biologically pure cultures of clone B9WTA, a cloneincluding the full-length nucleic acid sequence of PCVII B9 as depictedin FIGS. 4A-4B, was made with the American Type Culture Collection,10801 University Boulevard, Manassas, Va. on ______ and assignedAccession No. ______. The accession number indicated was assigned aftersuccessful viability testing, and the requisite fees were paid. Thedeposits were made under the provisions of the Budapest Treaty on theInternational Recognition of the Deposit of Microorganisms for thePurpose of Patent Procedure and the Regulations thereunder (BudapestTreaty). This assures maintenance of viable cultures for a period ofthirty (30) years from the date of deposit. The organisms will be madeavailable by the ATCC under the terms of the Budapest Treaty, whichassures permanent and unrestricted availability of the progeny to onedetermined by the U.S. Commissioner of Patents and Trademarks to beentitled thereto according to 35 U.S.C. §122 and the Commissioner'srules pursuant thereto (including 37 C.F.R. §1.12 with particularreference to 886 OG 638). Upon the granting of a patent, allrestrictions on the availability to the public of the deposited cultureswill be irrevocably removed.

These deposits are provided merely as convenience to those of skill inthe art, and are not an admission that a deposit is required under 35U.S.C. §112. The nucleic acid sequences of these genes, as well as theamino acid sequences of the molecules encoded thereby, are incorporatedherein by reference and are controlling in the event of any conflictwith the description herein.

Having thus described in detail preferred embodiments of the presentinvention, it is to be understood that the invention defined by theappended claims is not to be limited to particular details set forth inthe above description, as many apparent variations thereof are possiblewithout departing from the spirit or scope of the present invention.Modifications and variations of the method and apparatuses describedherein will be obvious to those skilled in the art, and are intended tobe encompassed by the following claims.

1-50. (canceled)
 51. An isolated immunogenic porcine circovirus type II(PCV-2) polypeptide comprising ORF 1 (SEQ ID NO:3).
 52. An immunogenicfragment comprising at least 10 contiguous amino acids of the isolatedPCV-2 polypeptide of claim 51, wherein the fragment contains an epitopeparticular to PCV-2.
 53. An isolated immunogenic porcine circovirus typeII (PCV-2) polypeptide having at least about 95% sequence identity toSEQ ID NO:3.
 54. An immunogenic fragment comprising at least 10contiguous amino acids of the isolated PCV-2 polypeptide of claim 53,wherein the fragment contains an epitope particular to PCV-2.
 55. Thepolypeptide of claim 53, having at least about 98% sequence identity toSEQ ID NO:3.
 56. An immunogenic fragment comprising at least 10contiguous amino acids of the isolated PCV-2 polypeptide of claim 55,wherein the fragment contains an epitope particular to PCV-2.
 57. Thepolypeptide of claim 53, wherein the polypeptide is a nativepolypeptide, a recombinant polypeptide, or a synthetic polypeptide. 58.An immunogenic composition comprising the polypeptide of claim 53 and apharmaceutically acceptable carrier.
 59. A method for eliciting animmunological response in a porcine host comprising administering aneffective amount of the composition of claim 58 to the porcine host. 60.An isolated immunogenic porcine circovirus type II (PCV-2) polypeptidecomprising ORF 2 (SEQ ID NO:9).
 61. An immunogenic fragment comprisingat least 10 contiguous amino acids of the isolated PCV-2 polypeptide ofclaim 60, wherein the fragment contains an epitope particular to PCV-2.62. An isolated immunogenic porcine circovirus type II (PCV-2)polypeptide having at least about 95% sequence identity to SEQ ID NO:9.63. An immunogenic fragment comprising at least 10 contiguous aminoacids of the isolated PCV-2 polypeptide of claim 62, wherein thefragment contains an epitope particular to PCV-2.
 64. The polypeptide ofclaim 62, having at least about 98% sequence identity to SEQ ID NO:9.65. An immunogenic fragment comprising at least 10 contiguous aminoacids of the isolated PCV-2 polypeptide of claim 64, wherein thefragment contains an epitope particular to PCV-2.
 66. The polypeptide ofclaim 62, wherein the polypeptide is a native polypeptide, a recombinantpolypeptide, or a synthetic polypeptide.
 67. An immunogenic compositioncomprising the polypeptide of claim 62 and a pharmaceutically acceptablecarrier.
 68. A method for eliciting an immunological response in aporcine host comprising administering an effective amount of thecomposition of claim 67 to the porcine host.
 69. An isolated immunogenicporcine circovirus type II (PCV-2) polypeptide comprising ORF 3 (SEQ IDNO:7).
 70. An immunogenic fragment comprising at least 10 contiguousamino acids of the isolated PCV-2 polypeptide of claim 69, wherein thefragment contains an epitope particular to PCV-2.
 71. An isolatedimmunogenic porcine circovirus type II (PCV-2) polypeptide having atleast about 95% sequence identity to SEQ ID NO:7.
 72. An immunogenicfragment comprising at least 10 contiguous amino acids of the isolatedPCV-2 polypeptide of claim 71, wherein the fragment contains an epitopeparticular to PCV-2.
 73. The polypeptide of claim 71, having at leastabout 98% sequence identity to SEQ ID NO:7.
 74. An immunogenic fragmentcomprising at least 10 contiguous amino acids of the isolated PCV-2polypeptide of claim 73, wherein the fragment contains an epitopeparticular to PCV-2.
 75. The polypeptide of claim 71, wherein thepolypeptide is a native polypeptide, a recombinant polypeptide, or asynthetic polypeptide.
 76. An immunogenic composition comprising thepolypeptide of claim 71 and a pharmaceutically acceptable carrier.
 77. Amethod for eliciting an immunological response in a porcine hostcomprising administering an effective amount of the composition of claim76 to the porcine host.
 78. An isolated immunogenic porcine circovirustype II (PCV-2) polypeptide comprising ORF 6 (SEQ ID NO:5).
 79. Animmunogenic fragment comprising at least 10 contiguous amino acids ofthe isolated PCV-2 polypeptide of claim 78, wherein the fragmentcontains an epitope particular to PCV-2.
 80. An isolated immunogenicporcine circovirus type II (PCV-2) polypeptide having at least about 95%sequence identity to SEQ ID NO:5.
 81. An immunogenic fragment comprisingat least 10 contiguous amino acids of the isolated PCV-2 polypeptide ofclaim 80, wherein the fragment contains an epitope particular to PCV-2.82. The polypeptide of claim 80, having at least about 98% sequenceidentity to SEQ ID NO:5.
 83. An immunogenic fragment comprising at least10 contiguous amino acids of the isolated PCV-2 polypeptide of claim 82,wherein the fragment contains an epitope particular to PCV-2.
 84. Thepolypeptide of claim 80, wherein the polypeptide is a nativepolypeptide, a recombinant polypeptide, or a synthetic polypeptide. 85.An immunogenic composition comprising the polypeptide of claim 80 and apharmaceutically acceptable carrier.
 86. A method for eliciting animmunological response in a porcine host comprising administering aneffective amount of the composition of claim 85 to the porcine host.